Drug Profile
AKP 501
Alternative Names: AKP-501; JR-041; Recombinant follicle-stimulating hormone - ASKA Pharmaceutical/JCR PharmaceuticalsLatest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator JCR Pharmaceuticals
- Developer ASKA Pharmaceutical
- Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
- Mechanism of Action Hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Female infertility
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-II for Female infertility in Japan (SC), prior to September 2021 (ASKA Pharmaceuticals pipeline, September 2021)
- 26 Apr 2019 Phase-II clinical trials in Female infertility in Japan (SC) (ASKA Pharmaceuticals pipeline, April 2019)
- 16 Feb 2016 Phase-I/II clinical trials in Female infertility in Japan (SC) before February 2016